Fjalldal S, Follin C, Svärd D, Rylander L, Gabery S, Petersen Å, Van Westen D, Sundgren P, Bjorkman-Burtscher I, Lätt J, Ekman B, Johanson A and Erfurth EM.European Journal of Endocrinology 178 (6): 577-587 (2018)AbstractCONTEXT:Patients with craniopharyngioma (CP) and hypothalamic lesions (HL) have cognitive deficits. Which neural pathways are affected is unknown.OBJECTIVE:To determine whether th

https://www.huntington-research.lu.se/microstructural-white-matter-alterations-and-hippocampal-volumes-are-associated-cognitive-deficits-0 - 2025-07-03

Petersén began medical school at Lund University (LU) in 1994 and started her PhD training in 1997. She received her PhD in experimental neuroscience in 2001 at the Faculty of Medicine at LU with Prof. Patrik Brundin as supervisor with a PhD thesis on Huntington’s disease (HD). She became an MD 2004 and a Reader (docent) in Neuroscience in 2006.Petersén started her research group TNU when she rece

https://www.huntington-research.lu.se/team/asa-petersen-md-phd - 2025-07-03

Full Name : Åsa Petersén Date of Birth: October 25th, 1974 Nationality: Swedish Address: Translational Neuroendocrinology (TNU), BMC D11, 221 84 Lund Phone: +46 46 222 16 86 E-mail address: Asa.Petersen@med.lu.se Professional appointments 2017-present Professor in Medical Research with specialization in Neuroscience, Medical Faculty, LU, combined position (s k förenad anställning) as Senior Consul

https://www.huntington-research.lu.se/curriculum-vitae-asa-petersen - 2025-07-03

Professor Åsa Petersén received the Fernström award 2018 for younger, successful researchers (Eric K Fernströms Svenska Pris 2018). The prize is awarded six researches at different Medical Faculties in Sweden, where each and one receives the sum of SEK 100 000. The Lund award ceremony took place on November 7 at “Forskningens dag”.   Dr Elisabeth Edholm Fernström handing over the award to Åsa Pete

https://www.huntington-research.lu.se/awards - 2025-07-03

Sanaz Gabery defended her doctoral thesis in TNU in 2015, was employed at Novo Nordisk A/S in Denmark and returned to Lund University in 2018. From 2017 to 2022 she combined her research with medical studies at Lund University. One of her projects aimed to determine the role of white matter pathology for the development and treatment of Huntington’s disease. Recent studies performed by Gabery and

https://www.huntington-research.lu.se/team/sanaz-gabery-phd - 2025-07-03

Translational studies addressing the main aims of the research group use experimental models and clinical material from patients with HD and FTD/ALS. Techniques used in the laboratory include detailed testing of motor, cognitive, social/emotional behaviours, metabolic function, stereotactic surgery, gene targeting and disease modelling using adeno-associated viral vectors (AAV), immunohistochemist

https://www.huntington-research.lu.se/translational-research-laboratory - 2025-07-03

Gorges M1, Vercruysse P1,2,3, Müller HP1, Huppertz HJ4, Rosenbohm A1, Nagel G5, Weydt P1, Petersén Å6, Ludolph AC3, Kassubek J1 and Dupuis L2.1 Department of Neurology, University of Ulm, Ulm, Germany2 Faculté de Médecine, INSERM UMR-S1118, Strasbourg, France3 Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France4 Swiss Epilepsy Centre, Klinik Lengg, Zurich, Switzer

https://www.huntington-research.lu.se/hypothalamic-atrophy-related-body-mass-index-and-age-onset-amyotrophic-lateral-sclerosis - 2025-07-03

2020: Project grant from Björklunds fond 2020: Project grant from Kungliga fysiografiska sällskapet, Sweden 2020: Project grant from Neuroförbundet. Sweden. 2018: Hjärnfondens Post doc stipend, Sweden 2018: Project grant from Neuroförbundet, Sweden 2016: Awarded best PhD thesis of 2015 at the Neurobiology section for my thesis New perspectives on pathology in Huntington's disease - characterizatio

https://www.huntington-research.lu.se/awards-and-grants-sanaz-gabery - 2025-07-03

Scientific presentations 2018: European HD Network (EHDN) Plenary meeting in Vienna, Austria. Poster presentation 2011-2014: The National Huntington’s Disease meeting, Gothenburg, Sweden. Oral presentation 2014: Hereditary disease foundation: The Milton Wexler Celebration of Life, Boston, USA. Poster presentation 2014: European HD Network (EHDN) Plenary meeting in Barcelona, Spain. Poster presenta

https://www.huntington-research.lu.se/scientific-presentations-sanaz-gabery - 2025-07-03

Awards2016: Lund University, EMV neurobiology section best PhD thesis award of 2016; Hypothalamic and Metabolic Dysfunction in Genetic Models of Huntington's Disease.2017: Hjärnfonden Postdoctoral FellowshipGrants2018: Project grant from The Royal Physiographic Society of Lund2017: Project grant from Hjärnfonden (co-applicant)2017: Project grant from Thorsten and Elsa Segerfalk Foundation2017: Pro

https://www.huntington-research.lu.se/awards-and-grants-rana-soylu-kucharz - 2025-07-03

Oral presentations2011: BAGADILICO retreat, Båstad, Sweden. Assessment of cellular specific hypothalamic dysfunction in HD.2012: NECTAR, Lund, Sweden. Effects of deletion of mutant huntingtin expression in Sim1 neurons in the BACHD mouse model of Huntington’s disease.2013: Gordon Research Conferences, CAG Triplet Repeat Disorders (GRS), Waterville Valley, USA. Long-term metabolic effects of huntin

https://www.huntington-research.lu.se/scientific-presentations-rana-soylu-kucharz - 2025-07-03

Follin C1, Fjalldal S1, Svärd D2,3, van Westen D2,3, Gabery S4, Petersén Å4, Lätt J3, Rylander L5 and Erfurth EM1.1. Department of Endocrinology, Skåne University Hospital, Lund, Sweden.2. Clinical Sciences Lund, Diagnostic Radiology, Lund University, Lund, Sweden.3. Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden.4. Translational Neuroendocrine Research Unit, Department of

https://www.huntington-research.lu.se/microstructure-alterations-hypothalamus-cranially-radiated-childhood-leukaemia-survivors-not - 2025-07-03

Kirik D1, Cederfjäll E1, Halliday G2 and Petersén Å3.1Brain Repair and Imaging in Neural Systems (B.R.A.I.N.S) Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.2Faculty of Medicine, University of New South Wales and Neuroscience Research Australia, Sydney, Australia.3Translational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund Universi

https://www.huntington-research.lu.se/gene-therapy-parkinsons-disease-disease-modification-gdnf-family-ligands - 2025-07-03

In connection to the Nordic Huntington Disease Research Meeting taking place in Lund, Sweden, on November 26 2019, we collect and process personal data in order to fulfill our task as the organizing body. The information we collect and process is the following: Name, title, affiliation, e-mail address and food preference, if necessary. The food preference is merely to ensure serving safe meals for

https://www.huntington-research.lu.se/personal-data-and-data-protection - 2025-07-03

Soylu-Kucharz R, Baldo B and Petersén Å.Scientific Reports Jun 23;6:28322 (2016)AbstractHypothalamic pathology, metabolic dysfunction and psychiatric symptoms are part of Huntington disease (HD), which is caused by an expanded CAG repeat in the huntingtin (HTT) gene. Inactivation of mutant HTT selectively in the hypothalamus prevents the development of metabolic dysfunction and depressive-like beh

https://www.huntington-research.lu.se/metabolic-and-behavioral-effects-mutant-huntingtin-deletion-sim1-neurons-bachd-mouse-model - 2025-07-03

Grants and Scholarships 2020: Neuroförbundet, Research grant 2020: Kungliga Fysiografiska Sällskapet i Lund, Research grant 2018: Anna Lisa Rosenberg Foundation, Research grant2018: Kungliga Fysiografiska Sällskapet i Lund, Research grant 2018: Hjärnfonden, Research grant 2017: Fredrik O Ingrid Thurings Foundation, Research grant2017: Neuroförbundet, Research grant 2017: Åhlén Foundation, Research

https://www.huntington-research.lu.se/awards-and-grants-rachel-cheong - 2025-07-03

Oral presentations Cheong RY, Hult Lundh S, Kirik D, Petersén Å. The psychiatric and metabolic phenotype of the BACHD mouse model of Huntington disease. 8th Plenary Meeting of EHDN, 2014, Spain. (Data blitz)Cheong RY, Ábrahám IM, Herbison AE. The estrogen receptor beta conundrum: A role in GnRH neurons? New Zealand Medical Science Congress, Aug 2011, Queenstown, New Zealand.Cheong RY, Kwakowsky A,

https://www.huntington-research.lu.se/scientific-presentations-rachel-cheong - 2025-07-03

Wagner L1,2,3, Björkqvist M4,5, Hult Lundh S5, Wolf R6,2, Börgel A2,7, Schlenzig D2, Ludwig HH5, Rahfeld JU2, Leavitt B7, Demuth HU2, Petersén Å4 and von Hörsten S8.Journal of Neurochemistry 137(5): 820-37 (2016)1Deutschsprachige Selbsthilfegruppe für Alkaptonurie (DSAKU) e.V, Stuttgart, Germany.2probiodrug AG, Halle (Saale, Germany.3Department of Experimental Therapy, Franz-Penzoldt-Center, Fried

https://www.huntington-research.lu.se/neuropeptide-y-npy-cerebrospinal-fluid-patients-huntingtons-disease-increased-npy-levels-and - 2025-07-03

Cheong RY, Gabery S and Petersén Å.Journal of Huntington's disease 8 (4): 375-391 (2019)AbstractHuntington's disease (HD) is a fatal genetic neurodegenerative disorder. It has mainly been considered a movement disorder with cognitive symptoms and these features have been associated with pathology of the striatum and cerebral cortex. Importantly, individuals with the mutant huntingtin gene suffer f

https://www.huntington-research.lu.se/role-hypothalamic-pathology-non-motor-features-huntingtons-disease - 2025-07-03

Petersén Å and Weydt P. Handbook of Clinical Neurology 15: 179-189 (2019) Abstract Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded cytosine-adenine-guanine triplet repeat in the huntingtin gene. The current diagnosis is based on the presence of typical motor signs in combination with a positive gene test. The motor onset of the disease is usually between 30

https://www.huntington-research.lu.se/psychopharmacology-huntington-disease - 2025-07-03